Wockhardt Share Price VS HLV Share Price In contrast, Wockhardt Pharma Limited, a prominent Indian pharmaceutical company with a global presence, has had a more volatile performance. Despite its solid global footprint across 30 countries, Wockhardt’s financial results in 2023 were largely negative, which has weighed on its share price. HLV Ltd. has demonstrated strong performance on the stock exchanges, with a consistent upward trend in its share prices, despite recent minor corrections. While the stock has experienced some short-term declines, the low percentage drop suggests that it can recover quickly, especially as market conditions stabilize. HLV’s share price prediction for 2025 and 2030 indicates a positive outlook, with analysts forecasting potential growth as the company continues to expand its business.
Wockhardt Share Price VS HLV Share Price Today Prediction
Wockhardt Pharma Limited has recently seen a downturn in its stock price, with the share price dropping by 3.94% as of the latest trading session, reflecting a current price around ₹578. This follows a broader downtrend since its March 1st high of ₹620, highlighting a period of decline in the stock’s performance. However, the company is taking steps to strengthen its position, such as planning to raise ₹400 crores through a QIP (Qualified Institutional Placement) to bolster its finances. Despite these efforts, Wockhardt has faced challenges in recent financial results, which have contributed to the stock’s volatility.
In contrast, HLV Ltd., with its current share price of ₹27.95, has also faced fluctuations, with a recent decline of 2.57% compared to its last closing. The company operates in a different sector, but its stock remains more volatile than Wockhardt’s, with prices ranging between ₹27.90 and ₹28.99. HLV’s high PE ratio of 78.52, significantly higher than the sector average, suggests that its stock may be overvalued relative to industry peers.
Wockhardt Share Price Target From 2024 To 2030
Year | Projected Wockhardt Share Price |
2024 | ₹1,456 |
2025 | ₹2,554 |
2026 | ₹3,678 |
2027 | |
2028 | ₹5,996 |
2029 | ₹7,225 |
2030 | ₹8,345 |
Wockhardt Share Price Target 2024, 2025, 2026, 2027, 2028, 2029 To 2030
Wockhardt Share Price Target From 2024 ₹1,456, 2025 ₹2,554, 2026 ₹3,678, 2027 ₹4,875, 2028 ₹5,996, 2029 ₹7,225 To 2030 ₹8,345 Full Information
HLV Share Price Target 2024 To 2030
Year | Initial Target | Mid-Year Target | Year-End Target |
|---|
2024 | ₹35.38 | ₹45.93 | ₹52.25 |
2025 | ₹53 | ₹49 | ₹58 |
2026 | ₹59 | ₹55 | ₹64 |
2027 | ₹65 | ₹61 | ₹72 |
2028 | ₹73 | ₹69 | ₹84 |
2029 | ₹86 | ₹81 | ₹96 |
2030 | ₹98 | ₹93 | ₹111 |
HLV Share Price Target 2024, 2025, 2026, 2027, 2028, 2029 To 2030
HLV Share Price Target 2024 ₹52.25, 2025 ₹58, 2026 ₹64, 2027 ₹72, 2028 ₹84, 2029 ₹96 To 2030 ₹111 Full Information
Wockhardt Pharma Share Price Outlook 2024 to 2030
Wockhardt Pharma, a prominent player in the Indian pharmaceutical and healthcare sector, has faced some financial challenges recently, with its share price declining by 3.94% and struggling to maintain its momentum after a high of ₹620 per share in March 2024. However, Wockhardt’s strategic initiatives, including its collaboration with Serum Life Sciences to produce vaccines and plans to raise ₹400 crores through a QIP, suggest long-term growth potential. The pharmaceutical sector has seen growing demand for health products globally.
Looking ahead, Wockhardt’s share price from 2024 to 2030 is expected to experience moderate recovery, provided it can turn around its recent negative financial results. Assuming successful execution of its strategic initiatives, such as expanding its vaccine production capacity and maintaining a strong foothold in global markets, the company may see its stock rise steadily over the next decade. By 2030, analysts anticipate that Wockhardt’s share price could range between ₹800 to ₹1,200, reflecting continued growth in the pharmaceutical sector.
HLV Ltd. Share Price Outlook 2024 to 2030
On the other hand, HLV Ltd., which is currently trading at ₹27.95, operates in a different sector with a relatively higher price volatility. Despite seeing some recent declines, with its stock price dropping by 2.57%, HLV has shown significant price fluctuations over the past year, ranging from ₹10.73 to ₹41.99. The company’s high PE ratio of 78.52 indicates that its stock is potentially overvalued compared to its sector, suggesting that HLV may face challenges in sustaining such high valuations in the long term unless its earnings growth can justify it.
From 2024 to 2030, HLV’s share price is likely to remain more volatile compared to Wockhardt, as it operates in a different market environment. HLV will need to prove its business model and maintain investor confidence to ensure consistent growth. Given the uncertainty in the market and HLV’s sector, the company’s stock price could experience more ups and downs, likely ranging between ₹30 to ₹60 by 2030, assuming it can navigate fluctuations in demand and continue executing on its business plans.
Comparison Summary (2024 to 2030)
- Wockhardt Pharma is expected to experience steady growth, driven by its strong presence in the pharmaceutical and healthcare sectors. Its share price is likely to rise from ₹578 in 2024 to a projected ₹800 to ₹1,200 by 2030, assuming successful implementation of its strategic initiatives and the continued demand for health-related products globally.
- HLV Ltd. will likely see moderate growth in its stock price, but it will remain more volatile. Given its current valuation and market challenges, its share price could range from ₹30 to ₹60 by 2030, reflecting the fluctuating nature of its business and market conditions.
In conclusion, Wockhardt Pharma offers a more stable growth potential due to its position in the healthcare and pharmaceutical sector, while HLV Ltd. faces more risks related to market volatility and will likely see slower growth in comparison.
